Total Payments
$1.5M
2024 Payments
$494,754
Companies
62
Transactions
2,515
Medicare Patients
30,206
Medicare Billing
$2.2M
Payment Breakdown by Category
Other$977,767 (66.2%)
Research$207,020 (14.0%)
Travel$131,683 (8.9%)
Consulting$120,778 (8.2%)
Food & Beverage$40,303 (2.7%)
Education$499.91 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $933,459 | 291 | 63.2% |
| Unspecified | $207,020 | 78 | 14.0% |
| Travel and Lodging | $131,683 | 287 | 8.9% |
| Consulting Fee | $120,778 | 75 | 8.2% |
| Honoraria | $44,308 | 12 | 3.0% |
| Food and Beverage | $40,303 | 1,762 | 2.7% |
| Education | $499.91 | 10 | 0.0% |
Payments by Type
General
$1.3M
2,437 transactions
Research
$207,020
78 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $247,583 | 424 | $0 (2024) |
| Janssen Biotech, Inc. | $185,616 | 280 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $151,579 | 132 | $0 (2024) |
| Eli Lilly and Company | $142,675 | 22 | $0 (2024) |
| LEO Pharma Inc. | $107,242 | 152 | $0 (2024) |
| GENZYME CORPORATION | $100,926 | 98 | $0 (2024) |
| Dermavant Sciences, Inc. | $92,941 | 104 | $0 (2024) |
| PFIZER INC. | $83,724 | 144 | $0 (2024) |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $78,733 | 121 | $0 (2024) |
| Arcutis Biotherapeutics, Inc. | $66,295 | 93 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $494,754 | 593 | GENZYME CORPORATION ($91,610) |
| 2023 | $329,895 | 382 | Janssen Biotech, Inc. ($87,880) |
| 2022 | $151,359 | 267 | Janssen Scientific Affairs, LLC ($61,945) |
| 2021 | $84,824 | 185 | E.R. Squibb & Sons, L.L.C. ($28,566) |
| 2020 | $56,215 | 170 | Janssen Scientific Affairs, LLC ($22,871) |
| 2019 | $152,892 | 342 | Eli Lilly and Company ($54,572) |
| 2018 | $150,020 | 295 | Eli Lilly and Company ($74,391) |
| 2017 | $58,091 | 281 | PFIZER INC. ($23,823) |
All Payment Transactions
2,515 individual payment records from CMS Open Payments — Page 1 of 101
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $147.15 | General |
| Category: Dermatology | ||||||
| 12/23/2024 | Ortho Dermatologics, a division of Bausch Health US, LLC | SILIQ (Drug) | Food and Beverage | In-kind items and services | $20.53 | General |
| Category: Dermatology | ||||||
| 12/23/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | ILUMYA (Biological) | Travel and Lodging | Cash or cash equivalent | $12.06 | General |
| Category: Dermatology | ||||||
| 12/23/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $5.89 | General |
| 12/20/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,500.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/20/2024 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,100.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/18/2024 | LEO Pharma Inc. | ADBRY (Biological) | Food and Beverage | In-kind items and services | $9.90 | General |
| Category: DERMATOLOGY | ||||||
| 12/17/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $3.20 | General |
| Category: IMMUNOLOGY | ||||||
| 12/16/2024 | LEO Pharma Inc. | ADBRY (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,430.00 | General |
| Category: DERMATOLOGY | ||||||
| 12/16/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $22.24 | General |
| Category: Dermatology | ||||||
| 12/16/2024 | Celgene Corporation | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $22.03 | General |
| Category: Immunology | ||||||
| 12/16/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $6.39 | General |
| Category: Dermatology | ||||||
| 12/13/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | Winlevi (Drug) | Food and Beverage | In-kind items and services | $26.02 | General |
| Category: Dermatology | ||||||
| 12/13/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $6.84 | General |
| 12/13/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $5.19 | General |
| Category: DERMATOLOGY | ||||||
| 12/11/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $102.02 | General |
| Category: Immunology | ||||||
| 12/11/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $9.55 | General |
| Category: DERMATOLOGY | ||||||
| 12/10/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $4.84 | General |
| Category: Dermatology | ||||||
| 12/10/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $1.36 | General |
| Category: DERMATOLOGY | ||||||
| 12/09/2024 | LEO Pharma Inc. | ADBRY (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,335.00 | General |
| Category: DERMATOLOGY | ||||||
| 12/09/2024 | Biofrontera Inc. | AMELUZ (Drug), BF-RhodoLED, XEPI | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| Category: DERMATOLOGY | ||||||
| 12/09/2024 | LEO Pharma Inc. | ADBRY (Biological) | Consulting Fee | Cash or cash equivalent | $73.95 | General |
| Category: DERMATOLOGY | ||||||
| 12/09/2024 | LEO Pharma Inc. | ADBRY (Biological) | Consulting Fee | Cash or cash equivalent | $52.93 | General |
| Category: DERMATOLOGY | ||||||
| 12/09/2024 | LEO Pharma Inc. | ADBRY (Biological) | Consulting Fee | Cash or cash equivalent | $50.92 | General |
| Category: DERMATOLOGY | ||||||
| 12/09/2024 | LEO Pharma Inc. | ADBRY (Biological) | Consulting Fee | Cash or cash equivalent | $45.23 | General |
| Category: DERMATOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $76,108 | 2 |
| A PHASE 2, MULTICENTER, RANDOMIZED, PARALLEL-ARM, PLACEBO- CONTROLLED STUDY OF LY3074828 IN SUBJECTS WITH MODERATE-TO- SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $40,299 | 3 |
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD) | Glenmark Pharmaceuticals Inc. | $17,634 | 25 |
| A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis | E.R. Squibb & Sons, L.L.C. | $15,375 | 1 |
| A MULTICENTER, LONG-TERM EXTENSION TO EVALUATE THE LONG-TERM SAFETY AND MAINTENANCE OF TREATMENT EFFECT OF LY3074828 IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-3 | Eli Lilly and Company | $14,720 | 3 |
| GBR830-204 | Ichnos Sciences Inc. | $12,795 | 1 |
| Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis | E.R. Squibb & Sons, L.L.C. | $11,488 | 1 |
| PSOSA (PSORIASIS SPECIAL AREAS) - A US-BASED SINGLE-ARM PROSPECTIVE MULTICENTER OBSERVATIONAL STUDY OF NAIL AND SCALP PSORIASIS IMPROVEMENT IN PATIENTS TREATED WITH IXEKIZUMAB | Eli Lilly and Company | $5,500 | 1 |
| A MULTICENTER, OPEN-LABEL, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $2,317 | 3 |
| A MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF LY2439821 TO ETANERCEPT AND PLACEBO IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $2,092 | 1 |
| ISB830-204 | Ichnos Sciences Inc. | $1,824 | 1 |
| A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $1,377 | 2 |
| Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable | SANOFI US SERVICES INC. | $1,366 | 11 |
| A PROSPECTIVE OBSERVATIONAL STUDY OF TREATMENT PATTERNS AND EFFECTIVENESS AND SAFETY OUTCOMES IN ADVANCED BASAL CELL CARCINOMA AND BASAL CELL CARCINOMA NEVUS SYNDROME PATIENTS | F. Hoffmann-La Roche AG | $1,350 | 1 |
| A Randomized Double Blind Placebo Controlled Parallel Group Dose Ranging Study Investigating the Efficacy Safety Pharmacokinetics and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate to Severe Atopic Dermatitis AD | Glenmark Pharmaceuticals Inc. | $1,256 | 14 |
| PROTOPIC APPLES | LEO Pharma AS | $650.00 | 1 |
| TRALOKINUMAB TRIAL IN ADJUNCT SETTING | LEO Pharma AS | $246.90 | 1 |
| A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2-Arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris | Valeant Pharmaceuticals North America LLC | $225.00 | 1 |
| A MULTICENTER STUDY WITH A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED INDUCTION DOSING PERIOD FOLLOWED BY A RANDOMIZED WITHDRAWAL MAINTENANCE DOSING PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-1 | Eli Lilly and Company | $221.80 | 1 |
| EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | Eli Lilly and Company | $104.58 | 1 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $47.71 | 2 |
| M15-997 | AbbVie, Inc. | $22.40 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 26 | 6,136 | 10,911 | $1.5M | $397,586 |
| 2022 | 31 | 7,856 | 14,258 | $2.1M | $559,230 |
| 2021 | 31 | 8,397 | 15,957 | $2.3M | $650,665 |
| 2020 | 32 | 7,817 | 14,677 | $2.2M | $564,459 |
Total Patients
30,206
Total Services
55,803
Medicare Billing
$2.2M
Procedure Codes
120
All Medicare Procedures & Services
120 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2023 | 1,710 | 2,754 | $455,206 | $104,557 | 23.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 1,117 | 1,296 | $205,566 | $68,583 | 33.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 484 | 531 | $143,368 | $38,504 | 26.9% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 473 | 511 | $106,224 | $29,124 | 27.4% |
| 96910 | Therapy procedure using ultraviolet radiation with tar or petroleum jelly application | Office | 2023 | 13 | 315 | $78,744 | $25,775 | 32.7% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 669 | 752 | $103,571 | $25,060 | 24.2% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 249 | 257 | $54,579 | $17,501 | 32.1% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 93 | 108 | $43,768 | $12,770 | 29.2% |
| 17262 | Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | Office | 2023 | 83 | 111 | $37,932 | $12,262 | 32.3% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 478 | 2,592 | $75,028 | $12,025 | 16.0% |
| J7308 | Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | Office | 2023 | 30 | 36 | $26,844 | $10,431 | 38.9% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 160 | 226 | $28,097 | $8,328 | 29.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 59 | 59 | $17,519 | $5,484 | 31.3% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 121 | 128 | $13,107 | $4,366 | 33.3% |
| 96574 | Application of light with debridement to destroy precancer skin growth | Office | 2023 | 17 | 20 | $11,862 | $4,019 | 33.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 59 | 59 | $11,327 | $3,095 | 27.3% |
| 17263 | Destruction of cancer skin growth of trunk, arms, or legs, 2.1-3.0 cm | Office | 2023 | 19 | 20 | $7,674 | $2,655 | 34.6% |
| 69100 | Biopsy of ear | Office | 2023 | 38 | 40 | $7,762 | $2,127 | 27.4% |
| 17272 | Destruction of cancer skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm | Office | 2023 | 15 | 17 | $6,298 | $2,054 | 32.6% |
| 96573 | Application of light by qualified health care professional to destroy precancer skin growth | Office | 2023 | 13 | 13 | $6,353 | $2,024 | 31.9% |
| 88304 | Pathology examination of tissue using a microscope, moderately low complexity | Office | 2023 | 46 | 55 | $6,765 | $1,693 | 25.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 71 | 201 | $6,605 | $1,648 | 25.0% |
| 17261 | Destruction of cancer skin growth of trunk, arms, or legs, 0.6-1.0 cm | Office | 2023 | 15 | 16 | $4,437 | $1,505 | 33.9% |
| 40490 | Biopsy of lip | Office | 2023 | 15 | 16 | $3,885 | $1,132 | 29.1% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 78 | 767 | $8,335 | $524.27 | 6.3% |
About Dr. Scott Guenthner, MD
Dr. Scott Guenthner, MD is a Dermatology healthcare provider based in Plainfield, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/31/2005. The National Provider Identifier (NPI) number assigned to this provider is 1396748778.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Scott Guenthner, MD has received a total of $1.5M in payments from pharmaceutical and medical device companies, with $494,754 received in 2024. These payments were reported across 2,515 transactions from 62 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($933,459).
As a Medicare-enrolled provider, Guenthner has provided services to 30,206 Medicare beneficiaries, totaling 55,803 services with total Medicare billing of $2.2M. Data is available for 4 years (2020–2023), covering 120 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Plainfield, IN
- Active Since 05/31/2005
- Last Updated 07/16/2025
- Taxonomy Code 207N00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1396748778
Products in Payments
- TREMFYA (Drug) $287,331
- RINVOQ (Biological) $150,930
- ADBRY (Biological) $106,719
- DUPIXENT (Biological) $100,261
- VTAMA (Drug) $92,941
- ILUMYA (Biological) $58,213
- SKYRIZI (Biological) $55,183
- EUCRISA (Drug) $52,418
- Zoryve (Drug) $47,907
- Tremfya (Drug) $42,795
- CIBINQO (Drug) $31,208
- Humira (Biological) $27,228
- Natroba (Drug) $18,200
- QBREXZA (Drug) $16,898
- YCANTH (Drug) $14,001
- GBR830-204 (Drug) $12,795
- Ilumya (Biological) $9,956
- COSENTYX (Biological) $9,876
- ILUMYA (tildrakizumab-asmn) injection (Biological) $9,868
- TALTZ (Drug) $9,299
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.